Literature DB >> 7834191

Relaxation of human isolated mesenteric arteries by vasopressin and desmopressin.

M C Martínez1, J M Vila, M Aldasoro, P Medina, B Flor, S Lluch.   

Abstract

1. The effects of vasopressin and deamino-8-D-arginine vasopressin (DDAVP, desmopressin) were studied in artery rings (0.8-1 mm in external diameter) obtained from portions of human omentum during the course of abdominal operations (27 patients). 2. In arterial rings under resting tension, vasopressin produced concentration-dependent, endothelium-independent contractions with an EC50 of 0.59 +/- 0.12 nM. The V1 antagonist d(CH2)5Tyr(Me)AVP (1 microM) and the mixed V1-V2 antagonist desGly-d(CH2)5D-Tyr(Et)ValAVP (0.01 microM) displaced the control curve to vasopressin to the right in a parallel manner without differences in the maximal responses. In the presence of indomethacin (1 microM) the contractile response to vasopressin was significantly increased (P < 0.01). 3. In precontracted arterial rings, previously treated with the V1 antagonist, d(CH2)5Tyr(Me)AVP (1 microM), vasopressin produced endothelium-dependent relaxation. This relaxation was reduced significantly (P < 0.05) by indomethacin (1 microM) and unaffected by the V1-V2 receptor antagonist desGly-d(CH2)5D-Tyr(Et)ValAVP (1 microM) or by NG-nitro-L-arginine methyl ester (L-NAME, 0.1 mM). 4. The selective V2 receptor agonist, DDAVP, caused endothelium-independent, concentration-dependent relaxations in precontracted arterial rings that were inhibited by the mixed V1-V2 receptor antagonist, but not by the V1 receptor antagonist or by pretreatment with indomethacin or L-NAME. 5. Results from this study suggest that vasopressin is primarily a constrictor of human mesenteric arteries by V1 receptor stimulation; vasopressin causes dilatation only during V1 receptor blockade. The relaxation appears to be mediated by the release of vasodilator prostaglandins from the endothelial cell layer and is independent of V2 receptor stimulation or release of nitric oxide. In contrast, the relaxation induced by DDAVP is largely dependent on stimulation of V2 receptors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7834191      PMCID: PMC1510102          DOI: 10.1111/j.1476-5381.1994.tb17005.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  24 in total

1.  Dose-response relationships for arginine vasopressin and synthetic analogs on three types of rat blood vessels: possible evidence for regional differences in vasopressin receptor sites within a mammal.

Authors:  B M Altura
Journal:  J Pharmacol Exp Ther       Date:  1975-05       Impact factor: 4.030

2.  Cardiovascular effects associated with antidiuretic activity of vasopressin after blockade of its vasoconstrictor action in dehydrated dogs.

Authors:  J F Liard
Journal:  Circ Res       Date:  1986-05       Impact factor: 17.367

3.  Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin.

Authors:  R H Michell; C J Kirk; M M Billah
Journal:  Biochem Soc Trans       Date:  1979-10       Impact factor: 5.407

4.  L-NAME antagonizes vasopressin V2-induced vasodilatation in dogs.

Authors:  J F Liard
Journal:  Am J Physiol       Date:  1994-01

Review 5.  The use of antagonists of vasopressin in studies of its physiological functions.

Authors:  W H Sawyer; M Manning
Journal:  Fed Proc       Date:  1985-01

6.  Depression of contractile responses in rat aorta by spontaneously released endothelium-derived relaxing factor.

Authors:  W Martin; R F Furchgott; G M Villani; D Jothianandan
Journal:  J Pharmacol Exp Ther       Date:  1986-05       Impact factor: 4.030

7.  Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis.

Authors:  S Jard; R C Gaillard; G Guillon; J Marie; P Schoenenberg; A F Muller; M Manning; W H Sawyer
Journal:  Mol Pharmacol       Date:  1986-08       Impact factor: 4.436

8.  Evidence for the direct effect of vasopressin on human and goat cerebral arteries.

Authors:  S Lluch; M V Conde; G Diéguez; A L López de Pablo; M C González; C Estrada; B Gómez
Journal:  J Pharmacol Exp Ther       Date:  1984-03       Impact factor: 4.030

9.  Vasoconstrictor-evoked prostaglandin synthesis in cultured vascular smooth muscle.

Authors:  A Hassid; C Williams
Journal:  Am J Physiol       Date:  1983-09

10.  Hemodynamic effects of antagonists of the vasoconstrictor action of vasopressin in conscious dogs.

Authors:  J F Liard; J C Spadone
Journal:  J Cardiovasc Pharmacol       Date:  1984 Jul-Aug       Impact factor: 3.105

View more
  5 in total

1.  Vasopressin as adjunct vasopressor for vasodilatory shock due to non-occlusive mesenteric ischemia.

Authors:  G Luckner; S Jochberger; V D Mayr; H Knotzer; W Pajk; V Wenzel; B Friesenecker; I Lorenz; M W Dünser
Journal:  Anaesthesist       Date:  2006-03       Impact factor: 1.041

Review 2.  Combined butalbital/acetaminophen/caffeine overdose: case files of the Robert Wood Johnson Medical School Toxicology Service.

Authors:  Christopher Bryczkowski; Ann-Jeannette Geib
Journal:  J Med Toxicol       Date:  2012-12

3.  alpha(2)-adrenoceptor and NPY receptor-mediated contractions of porcine isolated blood vessels: evidence for involvement of the vascular endothelium.

Authors:  R E Roberts; D A Kendall; V G Wilson
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

4.  Action of AT1 receptor antagonists on angiotensin II-induced tone in human isolated subcutaneous resistance arteries.

Authors:  R S Garcha; P S Sever; A D Hughes
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

5.  Exogenous vasopressin dose-dependently modulates gastric microcirculatory oxygenation in dogs via V1A receptor.

Authors:  Richard Truse; Steven Grewe; Anna Herminghaus; Jan Schulz; Andreas P M Weber; Tabea Mettler-Altmann; Inge Bauer; Olaf Picker; Christian Vollmer
Journal:  Crit Care       Date:  2019-11-12       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.